CLS_B: CLS accelerates neurosurgery growth, narrows losses, and targets profitability by 2026

About this update from Clinical Laserthermia Systems Ab Class B

Net sales surged over 270% year-over-year, driven by neurosurgery growth, while losses narrowed and the company shifted focus exclusively to high-margin neurosurgery. Board changes and cost reductions position CLS for sustainable profitability. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Clinical Laserthermia Systems Ab Class B